HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
26 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CD200
CD200 molecule
Chromosome 3 · 3q13.2
NCBI Gene: 4345Ensembl: ENSG00000091972.19HGNC: HGNC:7203UniProt: B4DDZ6
154PubMed Papers
20Diseases
1Drugs
0Pathogenic Variants
RESEARCH IMPACT
Trending
CLINICAL
Clinical Trials
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
positive regulation of transcription by RNA polymerase IIprotein bindingheterotypic cell-cell adhesionpositive regulation of macrophage activationbasal cell carcinomaskin canceractinic keratosisskin neoplasm
✦AI Summary

CD200 is a cell surface glycoprotein that functions as an immunoregulatory molecule by engaging CD200 receptors (CD200R) on myeloid cells to suppress inflammatory responses. Primary function: CD200 negatively regulates immune cell activation through CD200R signaling, which dampens macrophage and microglia-mediated inflammatory responses 12. Mechanism: CD200-CD200R interaction induces downstream signaling through Dok2 phosphorylation while suppressing NF-κB activation 3. This engagement reduces production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and suppresses macrophage-mediated cytotoxicity and phagocytosis 14. Disease relevance: Dysregulation of CD200-CD200R signaling contributes to multiple pathologies. In pancreatic cancer, CD200 expression promotes myeloid-derived suppressor cell (MDSC) expansion, creating immunosuppression that limits checkpoint immunotherapy efficacy 5. In diabetic retinopathy, dysregulated CD200 signaling enhances microglial activation and neuronal damage 2. CD200 expression is dysregulated in asthma pathogenesis 6. Clinical significance: CD200 blockade enhances anti-tumor immunity and synergizes with PD-1 checkpoint inhibitors in pancreatic cancer 5. CD200R antagonism attenuates diabetic retinopathy progression 2. During inflammatory resolution, pro-resolving CD200+ fibroblasts stabilize type 2 immune responses 4, suggesting CD200 manipulation could promote healing.

Sources cited
1
CD200 expressed in PDAC microenvironment promotes MDSC expansion and immunosuppression; blocking CD200 reduces tumor progression and enhances checkpoint immunotherapy efficacy
PMID: 32581043
2
CD200-CD200R signaling dysregulation in diabetes drives microglial activation and retinal neurodegeneration; targeting CD200R prevents visual dysfunction and inflammation
PMID: 37903272
3
CD200 pathway is dysregulated in asthma; CD200 receptor modulation improves preclinical asthma outcomes
PMID: 31077782
4
CD200 suppresses macrophage-mediated xenogeneic cytotoxicity and phagocytosis through CD200R engagement
PMID: 28573328
5
CD200-CD200R interaction induces Dok2 phosphorylation and suppresses IκB phosphorylation to reduce pro-inflammatory responses
PMID: 38751087
6
Pro-resolving CD200+DKK3+ fibroblasts stabilize type 2 innate lymphoid cell phenotype and promote inflammatory resolution via CD200-CD200R1 signaling
PMID: 38396288
7
CD200 is highly expressed on lymphatic endothelial cells and mediates CD200-CD200R interactions with myeloid cells to regulate skin inflammation
PMID: 35326506
Disease Associationsⓘ20
basal cell carcinomaOpen Targets
0.35Weak
skin cancerOpen Targets
0.35Weak
actinic keratosisOpen Targets
0.35Weak
skin neoplasmOpen Targets
0.35Weak
dermatomycosisOpen Targets
0.35Weak
ulcerative colitisOpen Targets
0.35Weak
Crohn's diseaseOpen Targets
0.34Weak
cutaneous melanomaOpen Targets
0.34Weak
sarcoidosisOpen Targets
0.34Weak
anal neoplasmOpen Targets
0.17Weak
colonic neoplasmOpen Targets
0.17Weak
rectal neoplasmOpen Targets
0.16Weak
chronic lymphocytic leukemiaOpen Targets
0.13Weak
neoplasmOpen Targets
0.13Weak
acute myeloid leukemiaOpen Targets
0.11Weak
Miyoshi myopathyOpen Targets
0.10Weak
systemic lupus erythematosusOpen Targets
0.09Suggestive
myelodysplastic syndromeOpen Targets
0.09Suggestive
Parkinson diseaseOpen Targets
0.09Suggestive
head and neck squamous cell carcinomaOpen Targets
0.09Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets1
SAMALIZUMABPhase II
OX-2 membrane glycoprotein inhibitor
acute myeloid leukemia by FAB classification
Related Genes
CD47Protein interaction100%PTPRCProtein interaction92%CX3CR1Protein interaction83%CX3CL1Protein interaction83%TREM2Protein interaction77%CD200R1Protein interaction72%
Tissue Expression6 tissues
Brain
100%
Ovary
26%
Bone Marrow
17%
Heart
13%
Lung
8%
Liver
1%
Gene Interaction Network
Click a node to explore
CD200CD47PTPRCCX3CR1CX3CL1TREM2CD200R1
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt P41217
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.85LoF Tolerant
pLIⓘ
0.02Tolerant
Observed/Expected LoF0.52 [0.34–0.85]
RankingsWhere CD200 stands among ~20K protein-coding genes
  • #2,929of 20,598
    Most Researched154 · top quartile
  • #7,372of 17,882
    Most Constrained (LOEUF)0.85
Genes detectedCD200
Sources retrieved26 papers
Response time—
📄 Sources
26▼
1
CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
PMID: 32581043
J Immunother Cancer · 2020
1.00
2
Dysregulated CD200-CD200R signaling in early diabetes modulates microglia-mediated retinopathy.
PMID: 37903272
Proc Natl Acad Sci U S A · 2023
0.90
3
CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth.
PMID: 40461553
Nat Commun · 2025
0.80
4
CD200 in asthma.
PMID: 31077782
Int J Biochem Cell Biol · 2019
0.80
5
Proteomic Analysis of Unbounded Cellular Compartments: Synaptic Clefts.
PMID: 27565350
Cell · 2016
0.70